320 Years of History
Gold Member
I'm not going to pretend to understand what the "Epipen issue" is all about. The hoopla of late about it seems completely absurd. What I mean is that epinephrine is a drug of sorts (strictly speaking, it's the hormone adrenalin) and the EpiPen is a delivery mechanism for that drug.
I know that epinephrine is a generic ingredient that doesn't fall under patent protection. That tells me that the "EpiPen issue" must pertain to the delivery method not the drug.
The central question in my mind, then, is this. Why aren't other producers entering the market with competing products?
Now, do I have an issue with Mylan charging whatever it charges for EpiPens? No. Why would or should I? What is there to say about what a producer charges for their goods and services?
I know that epinephrine is a generic ingredient that doesn't fall under patent protection. That tells me that the "EpiPen issue" must pertain to the delivery method not the drug.
The central question in my mind, then, is this. Why aren't other producers entering the market with competing products?
Now, do I have an issue with Mylan charging whatever it charges for EpiPens? No. Why would or should I? What is there to say about what a producer charges for their goods and services?